A pharmaceutical company that whistleblowers alleged paid doctors to prescribe its main drug and urged salespeople to push it as a way to control unruly dementia patients will pay more than $100 million to settle government fraud allegations. Each of these three whistleblowers will receive a portion of the millions Avanir has agreed to pay. The DOJ said Avanir admits it paid one of those doctors "to induce him to not only maintain, but increase his prescription volume." This came as the government attempted to crack down on the use of antipsychotics in restraining elderly dementia patients. While the government settlement resolves fraud claims against the company, the former employee is still suing Avanir for unlawful retaliation.